Reuters logo
BRIEF-Aerie Pharmaceuticals announces drug delivery asset acquisition
October 5, 2017 / 10:11 AM / 2 months ago

BRIEF-Aerie Pharmaceuticals announces drug delivery asset acquisition

Oct 5 (Reuters) - Aerie Pharmaceuticals Inc:

* Aerie Pharmaceuticals announces drug delivery asset acquisition to further advance its retinal disease program

* Aerie Pharmaceuticals Inc - has acquired from Envisia Therapeutics Inc rights to use print technology in ophthalmology and certain other assets

* Aerie Pharmaceuticals Inc - ‍Envisia will receive an initial $25 million in form of a combination of cash and Aerie common stock​

* Aerie Pharmaceuticals Inc - expect to initiate ‍clinical trials for AR-13154 within next 18 to 24 months​

* Aerie Pharmaceuticals Inc - ‍in addition, Aerie acquired Envisia’s intellectual property rights relating to ENV1105​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below